Literature DB >> 28741690

Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States.

Edward Faught1, François Laliberté2, Zhixiao Wang3, Victoria Barghout4, Batool Haider5, Dominique Lejeune2, Guillaume Germain2, Jiyoon Choi3, Aneesha Wagh5, Mei Sheng Duh5.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate changes in health care resource utilization following the initiation of perampanel for the treatment of epilepsy in the United States.
METHODS: Health care claims from Symphony Health's Integrated Dataverse database between December 2012 and November 2015 were analyzed. Patients newly initiated on perampanel, having ≥1 epilepsy (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 345.xx, ICD-10-CM code G40.xxx) or nonfebrile convulsion (ICD-9-CM code 780.39, ICD-10-CM code R56.9) diagnosis, and having ≥6 months of baseline and observation periods were included. Patients <12 years old at perampanel initiation were excluded.
RESULTS: Of the 2,508 perampanel patients included in the study, the mean [median] (±standard deviation [SD]) age was 35.8 [34] (±16.0) years and 56.2% were female. The mean [median] (±SD) observation duration was 459.8 [462] (±146.3) days in the postperampanel period. The postperampanel period was associated with significantly lower rates of all health care resource utilization outcomes than the pre-period. For the post- versus pre-period, perampanel users had 42.3 versus 53.8 overall hospitalizations per 100 person-years (rate ratio [RR] = 0.80, p < 0.001) and 1,240.2 versus 1,343.8 outpatient visits per 100 person-years (RR = 0.91, p < 0.001). Epilepsy-related hospitalizations and outpatient visits were 25.2 versus 33.6 per 100 person-years (RR = 0.76, p < 0.001) and 327.0 versus 389.0 per 100 person-years (RR = 0.84, p < 0.001), respectively. Additionally, a significantly lower rate of status epilepticus in the post-period (1.8 events per 100 person-years) was observed compared to the pre-period (4.4 events per 100 person-years; RR = 0.43, p < 0.001). The monthly time trend of hospitalizations showed an increasing trend leading up to the initiation of perampanel, after which the hospitalizations decreased steadily. SIGNIFICANCE: Use of perampanel for the treatment of epilepsy was associated with significant reduction in all-cause and epilepsy-related health care resource utilization, including hospitalizations, especially for status epilepticus, and outpatient visits. Wiley Periodicals, Inc.
© 2017 International League Against Epilepsy.

Entities:  

Keywords:  Antiepileptic drugs; Epilepsy; Generalized tonic-clonic seizures; Health care resource utilization; Partial-onset seizures; Perampanel

Mesh:

Substances:

Year:  2017        PMID: 28741690     DOI: 10.1111/epi.13857

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  2 in total

1.  Patient-Reported Outcome Measures in Adult Patients Diagnosed with Epilepsy Being Treated with Perampanel.

Authors:  Brian D Moseley; Shaloo Gupta; Nate Way; Jonathon Wright; John C Rowland; Victoria E Barghout; Feride Frech; Craig Plauschinat
Journal:  Patient Relat Outcome Meas       Date:  2022-02-09

2.  Real-world analysis of hospitalizations in patients with epilepsy and treated with perampanel.

Authors:  Edward Faught; Xuan Li; Jiyoon Choi; Manoj Malhotra; Russell L Knoth
Journal:  Epilepsia Open       Date:  2021-08-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.